Short Interest in INVO Fertility, Inc (NASDAQ:IVF) Declines By 65.8%

INVO Fertility, Inc (NASDAQ:IVF) was the recipient of a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 260,114 shares, a drop of 65.8% from the June 30th total of 760,242 shares. Approximately 14.6% of the shares of the stock are short sold. Based on an average daily volume of 358,678 shares, the short-interest ratio is presently 0.7 days.

INVO Fertility Price Performance

NASDAQ IVF traded up $0.02 during trading hours on Tuesday, reaching $0.98. 88,412 shares of the company’s stock were exchanged, compared to its average volume of 1,676,618. The firm has a fifty day moving average of $1.44 and a 200-day moving average of $3.07. INVO Fertility has a one year low of $0.91 and a one year high of $90.80. The stock has a market cap of $1.75 million, a PE ratio of -0.00 and a beta of 2.28. The company has a current ratio of 0.90, a quick ratio of 0.87 and a debt-to-equity ratio of 0.05.

INVO Fertility (NASDAQ:IVF) last issued its quarterly earnings data on Monday, June 22nd. The company reported ($3.38) earnings per share (EPS) for the quarter. The business had revenue of $2.02 million during the quarter. INVO Fertility had a negative net margin of 183.75% and a negative return on equity of 420.62%.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC acquired a new stake in INVO Fertility, Inc (NASDAQ:IVF) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility at the end of the most recent quarter. Hedge funds and other institutional investors own 12.02% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.